Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
Previstage™ GCC
The Previstage™ GCC Colorectal Cancer Staging Test is now offered by DiagnoCure Oncology Laboratories directly to clinicians.
Access to DiagnoCure Oncology Laboratories website »
PCA3 Molecular Marker
The PCA3 test for prostate cancer is available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay.
Special Media Coverage on PCA3 »
External site on PCA3, Ismar Healthcare »
Shc Proteins for Breast, Colon and
other Cancers
On August 2007, DiagnoCure acquired lead proprietary prognostic tests with applications in five tumor types, including breast and colon.
Special Announcement
DiagnoCure launches Previstage™ GCC
Colorectal Cancer Staging Test
INVESTORS
|
0.98
+0.09
|
Open: 0.97
$CAN.
Quotes are delayed. |
- Third quarter 2008 (PDF)
- Corporate Fact Sheet (PDF)
- Corporate Brochure (PDF)
- 2007 Annual Report (PDF)
Latest News
December 17, 2008 - DiagnoCure announces fourth quarter 2008 and year-end results
December 5, 2008 - DiagnoCure announces Q4 and full year 2008 earnings conference call and webcast
Upcoming Events
January 15 - 17, 2009
Gastrointestinal Cancers Symposium
San Francisco, California, U.S.A.
March 5 - 8, 2009
Society of Surgical Oncology Annual Cancer Symposium
Phoenix, Arizona, U.S.A.
March 7 - 13, 2009
USCAP Annual Meeting
Boston, Massachussetts, U.S.A.